Literature DB >> 31834674

Sinonasal quality-of-life declines in cystic fibrosis patients with pulmonary exacerbations.

Chetan Safi1, Emily DiMango2, Claire Keating2, Zian Zhou3, David A Gudis1.   

Abstract

BACKGROUND: In cystic fibrosis (CF), the relationship between chronic rhinosinusitis (CRS) and pulmonary disease is poorly understood. The purpose of this study was to evaluate the relationship between scores on the 22-item Sino-Nasal Outcome Test (SNOT-22) and CF Questionnaire-revised for adolescents and adults over 14 (CFQ-R 14+), and pulmonary function tests in 2 cohorts of CF patients: those at their baseline health and those with a pulmonary exacerbation.
METHODS: Patients >18 years old seen in a Cystic Fibrosis Foundation-accredited clinic completed the SNOT-22 and CFQ-R 14+ instruments. Patients presenting for routine care represented the baseline cohort. Patients diagnosed with a pulmonary exacerbation represented the exacerbation cohort. Average SNOT-22 and CFQ-R 14+ scores for both groups were compared using a 2-sample t test, and correlation coefficient was calculated.
RESULTS: One hundred three patients were enrolled over 3 months (30 exacerbations and 73 baseline). Patients' mean age was 32 years (56% female and 44% male). Average SNOT-22 and CFQ-R 14+ scores were significantly worse for exacerbation patients (p = 0.001 and p = 0.0003, respectively). Percent predicted forced expiratory volume in 1 second and forced vital capacity were both higher for baseline patients (p = 0.002 and p = 0.001, respectively). Average SNOT-22 score for all patients was worse than the average score for non-CF, non-CRS patients.
CONCLUSION: CF patients with pulmonary exacerbations have worse SNOT-22 and CFQ-R 14+ scores than CF patients at their baseline health. This finding suggests a temporal relationship between sinonasal and pulmonary quality of life, and that worsening of both is associated with reduced pulmonary function.
© 2019 ARS-AAOA, LLC.

Entities:  

Keywords:  SNOT-22; chronic rhinosinusitis; quality of life

Mesh:

Year:  2019        PMID: 31834674     DOI: 10.1002/alr.22485

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  2 in total

1.  Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.

Authors:  Amanda L Stapleton; Adam J Kimple; Jennifer L Goralski; S Mehdi Nouraie; Barton F Branstetter; Amber D Shaffer; Joseph M Pilewski; Brent A Senior; Stella E Lee; Anna C Zemke
Journal:  J Cyst Fibros       Date:  2022-03-14       Impact factor: 5.527

2.  Manuka honey versus saline sinus irrigation in the treatment of cystic fibrosis-associated chronic rhinosinusitis: A randomised pilot trial.

Authors:  Victoria S Lee; Ian M Humphreys; Patricia L Purcell; Greg E Davis
Journal:  Clin Otolaryngol       Date:  2020-10-02       Impact factor: 2.597

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.